BURGWEDEL, Germany, March 27, 2018 /PRNewswire/ -- MYR Pharma GmbH, focused on the development of Myrcludex B, a novel drug for the treatment of HepatitisB and Delta, today announced a number of oral and poster presentations at the upcoming International Liver Congress organized by the European Association for the Study of the Liver (EASL) in Paris, France. The presentations
An additional presentation will be given at the 15th Hepatitis Delta International Network (HDIN) Meeting during EASL:
About Myrcludex B
Myrcludex B is a first-in-class entry inhibitor for the treatment of chronic hepatitis B (HBV) and its co-infection hepatitis Delta. The drug has received Orphan Designation for treatment of HDV infection from the EMA and FDA, and PRIME scheme eligibility from the EMA.
To find out more about Myrcludex B, visit http://myr-pharma.com/science/about-myrcludex-b.
About MYR Pharma
MYR Pharma GmbH is a German clinical stage biotechnology company focused on the development of drugs for the treatment of chronic hepatitis B and Delta virus infections.
Contact: Alexey Eliseev, +1-617-953-0767
View original content:http://www.prnewswire.com/news-releases/myr-pharma-announces-multiple-presentations-at-the-european-association-for-the-study-of-the-liver-easl-meeting-300620217.html
SOURCE MYR Pharma
Subscribe to our Free Newsletters!
Complex regional pain syndrome (CRPS) is rare chronic pain disorder usually involving an arm or ...
Polyarthritis refers to pain in four or more joints simultaneously due to various causes ranging ...
Gardner or Gardner''s syndrome, also known as familial adenomatous polyposis (FAP), is an autosomal ...View All